Inotiv (NOTV) Panoramica del titolo
Inotiv, Inc. fornisce servizi di scoperta e sviluppo di farmaci non clinici e analitici alle industrie farmaceutiche e di dispositivi medici negli Stati Uniti, nei Paesi Bassi e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
NOTV Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$1.2
FV
74.2% sottovalutato sconto intrinseco4.9k
users have viewed this narrative9users have liked this narrative
3users have commented on this narrative
28users have followed this narrative
Concorrenti di Inotiv, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.31 |
| Massimo di 52 settimane | US$3.32 |
| Minimo di 52 settimane | US$0.22 |
| Beta | 3.83 |
| Variazione di 1 mese | 26.20% |
| Variazione a 3 mesi | 8.57% |
| Variazione di 1 anno | -84.77% |
| Variazione a 3 anni | -95.21% |
| Variazione a 5 anni | -98.81% |
| Variazione dall'IPO | -96.25% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.
Aggiornamento della narrazione • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
Aggiornamento della narrazione • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.Aggiornamento della narrazione • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.Recent updates
Aggiornamento della narrazione • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.Aggiornamento della narrazione • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.Aggiornamento della narrazione • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.Aggiornamento della narrazione • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
Aggiornamento della narrazione • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.Aggiornamento della narrazione • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.Aggiornamento della narrazione • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.Aggiornamento della narrazione • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.Aggiornamento della narrazione • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.Aggiornamento della narrazione • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.Nuova narrazione • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Aggiornamento della narrazione • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).Aggiornamento della narrazione • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.Aggiornamento della narrazione • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).Aggiornamento della narrazione • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).Aggiornamento della narrazione • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.Articolo di analisi • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...Articolo di analisi • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nuova narrazione • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.Articolo di analisi • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...Articolo di analisi • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...Articolo di analisi • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...Articolo di analisi • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...Articolo di analisi • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...Articolo di analisi • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| NOTV | US Life Sciences | US Mercato | |
|---|---|---|---|
| 7D | 5.1% | -5.3% | 1.1% |
| 1Y | -84.8% | 2.9% | 26.7% |
Ritorno vs Industria: NOTV ha avuto una performance inferiore rispetto al US Life Sciences che ha registrato un rendimento 2.9 % nell'ultimo anno.
Rendimento vs Mercato: NOTV ha avuto una performance inferiore al mercato US che ha registrato un rendimento 26.7 % nell'ultimo anno.
Volatilità dei prezzi
| NOTV volatility | |
|---|---|
| NOTV Average Weekly Movement | 26.0% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di NOTV è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di NOTV è aumentata da 18% a 26% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1974 | 1,996 | Bob Leasure | www.inotiv.com |
Inotiv, Inc. fornisce servizi analitici e non clinici per la scoperta e lo sviluppo di farmaci alle industrie farmaceutiche e di dispositivi medici negli Stati Uniti, nei Paesi Bassi e a livello internazionale. L'azienda opera attraverso due segmenti, Discovery and Safety Assessment (DSA) e Research Models and Services (RMS). Il segmento DMS produce strumenti scientifici per la ricerca nelle scienze della vita e il relativo software per l'uso da parte di aziende farmaceutiche, università, centri di ricerca governativi e istituti di ricerca medica con la linea di prodotti BASi.
Inotiv, Inc. Riepilogo dei fondamenti
| NOTV statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$10.80m |
| Utili (TTM) | -US$86.97m |
| Ricavi(TTM) | US$507.36m |
0.0x
Rapporto P/S-0.1x
Rapporto P/ENOTV è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| NOTV Conto economico (TTM) | |
|---|---|
| Ricavi | US$507.36m |
| Costo del fatturato | US$390.95m |
| Profitto lordo | US$116.41m |
| Altre spese | US$203.38m |
| Utili | -US$86.97m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -2.53 |
| Margine lordo | 22.94% |
| Margine di profitto netto | -17.14% |
| Rapporto debito/patrimonio netto | 549.2% |
Come si è comportato NOTV nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/14 09:40 |
| Prezzo dell'azione a fine giornata | 2026/05/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Inotiv, Inc. è coperta da 5 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |